Besivance (besifloxacin) NDC 85766-257

NDC codes

FDA NDC Directory

Product NDC (as listed)85766-257Labeler and product segments. Claims need a package NDC.

Product NDC at billing width85766-0257Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
85766-257-05	85766025705	1 BOTTLE, DROPPER in 1 CARTON (85766-257-05) / 5 mL in 1 BOTTLE, DROPPERMarketed from Jul 23, 2026

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Besivance
Generic name (nonproprietary): besifloxacin
Active ingredients: Besifloxacin — 6 mg/mL
Dosage form: Suspension
Route: Ophthalmic
Labeler: Sportpharm LLC
Product type: Prescription drug
Marketing category: NDA — New Drug ApplicationApplication NDA 022308
Marketing start: May 28, 2009
Listing expires: Dec 31, 2027
Other FDA classes: Quinolones (Chemical structure)
Identifiers: Product ID 85766-257_57410dc3-5ac5-b323-e063-6394a90a1a0aSPL ID 57410dc3-5ac5-b323-e063-6394a90a1a0aSPL set ID 80bf4981-4f86-4d25-83a5-7d5dfe0b22e0RxCUI 850305, 850309UNII BFE2NBZ7NX
Pharmacologic class: Quinolone Antimicrobial

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Ophthalmic products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N485766025705 followed by a unit qualifier and the quantity

Package 85766-0257-05. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Jul 23, 2026.

Indications (excerpt from the label)

BESIVANCE ® (besifloxacin ophthalmic suspension) 0.6% is indicated for the treatment of bacterial conjunctivitis caused by susceptible isolates of the following bacteria: Aerococcus viridans* CDC coryneform group G Corynebacterium pseudodiphtheriticum* Corynebacterium striatum* Haemophilus influenzae Moraxella catarrhalis* Moraxella lacunata* Pseudomonas aeruginosa* Staphylococcus aureus Staphylococcus epidermidis Staphylococcus hominis* Staphylococcus lugdunensis* Staphylococcus warneri* Streptococcus mitis group Streptococcus oralis Streptococcus pneumoniae Streptococcus salivarius* *Efficacy for this organism was studied in fewer than 10 infections. BESIVANCE ® (besifloxacin ophthalmic su…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under NDA 022308

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under NDA 022308
Product	Strength	Form · route	Labeler	Product NDC
Besivancebesifloxacin	Besifloxacin 6 mg/mL	SuspensionOphthalmic	Bausch & Lomb Americas Inc.	82260-466
Besivancebesifloxacin	Besifloxacin 6 mg/mL	SuspensionOphthalmic	Sportpharm LLC	85766-260
Besivancebesifloxacin	Besifloxacin 6 mg/mL	SuspensionOphthalmic	Bausch & Lomb Incorporated	24208-446